Coley Pharmaceutical Group to Present at the Lazard Capital Markets Fourth Annual Healthcare ... ( WELLESLEY Mass. Nov. 26 /- ColeyP...)

Coley Pharmaceutical Group to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference

Date:11/26/2007

WELLESLEY, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY), today announced that Robert L. Bratzler, Ph.D., President & Chief Executive Officer, will be presenting a corporate update at the upcoming Lazard Capital Markets Fourth Annual Healthcare Conference at 10:00am ET on November 27th, 2007 at the New York Palace Hotel.

Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the "Investor Events" page in the Investor Center section of the Coley website for two weeks until December 11th, 2007.

About Coley Pharmaceutical Group

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, autoimmune diseases, allergy and asthma disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis Vaccines and the United States government.

The company recently announced that it has entered into an agreement to be acquired by Pfizer Inc through a cash tender offer at a price of $8.00 per share. For further information on Coley Pharmaceutical Grou
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Coley Pharmaceutical Group Adopts Shareholder Rights Plan
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products

Post Your Comments:

Coley Pharmaceutical Group to Present at the Lazard Capital Markets Fourth Annual Healthcare ...( WELLESLEY Mass. Nov. 26 /- ColeyP...)